In the first three months of 1997, Degussa of Germany achieved a rise of25% in its pretax profits to 233 million Deutschemarks ($137 million). The company said that the growth was driven by its businesses outside Germany. Group sales for the quarter were 7.2 billion marks, an increase of 5%.
Some analysts warned that the firm's growth was flattered by lower restructuring costs after provisions were made in 1996 for reorganization of its metals division, and the consolidation of its US acquisition, Muro Pharmaceuticals, reported the Financial Times. One analyst told the FT that the firm is doing well despite the weak economy in Germany, and has a strong business in the USA. The firm's share price slipped slightly after the announcement on profit-taking.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze